Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 juil. 2022 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 juin 2022 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at Upcoming Investor Conferences
26 mai 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric Cancer
19 mai 2022 07h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
09 mai 2022 07h00 HE
|
Mersana Therapeutics, Inc.
Advanced UpRi development across UPLIFT, UPGRADE, and UP-NEXT clinical trialsPrepared for expected initiation of patient dosing in Phase 1 clinical trials of XMT-1660 and XMT-2056 in mid-2022Entered...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 mai 2022 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Host First Quarter 2022 Conference Call on May 9, 2022
02 mai 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 avr. 2022 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting
05 avr. 2022 08h00 HE
|
Mersana Therapeutics, Inc.
XMT-1660 demonstrates robust activity in preclinical models of breast cancer XMT-2056 demonstrates robust activity as monotherapy, in combination with standard of care therapies and in both HER2-high...
Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer
15 mars 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...